Compare Adaptive Biotechnologies Corp (ADPT) vs W W Grainger Inc (GWW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs W W Grainger Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.87 (market cap $4.04B), while W W Grainger Inc trades at $1,308.84 (market cap $61.32B). The key difference: W W Grainger Inc is far larger — about 15.2× Adaptive Biotechnologies Corp's market cap, and W W Grainger Inc pays a 0.77% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GWW | |
|---|---|---|
Market Cap | $4.04B | $61.32B |
Sector | Health | Technology |
52-Week High | $25.45 | $1.40K |
52-Week Low | $12.30 | $918.18 |
Enterprise Value | $4.10B | $63.53B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.
Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →
